[
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates",
    "summary": "LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.",
    "url": "https://finnhub.io/api/news?id=8f13ce21770fcdb0b591ca5e8e792d3efae92641786efb67e770e4074d09557e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748613600,
      "headline": "Pharma Stock Roundup: LLY's New Deal, GSK & SNY's Pipeline Updates",
      "id": 134905237,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "LLY to acquire SiteOne for up to $1 billion. GSK's antibiotic study ends early for efficacy. MRNA loses H5 flu vaccine funding, while SNY sees mixed COPD data.",
      "url": "https://finnhub.io/api/news?id=8f13ce21770fcdb0b591ca5e8e792d3efae92641786efb67e770e4074d09557e"
    }
  },
  {
    "ts": null,
    "headline": "abrdn Healthcare Investors Q1 2025 Commentary",
    "summary": "abrdn Healthcare Investors Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=08a995b94c9843618fb019a74515636093294d133726b11dc86cee43c76ca7fd",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748595900,
      "headline": "abrdn Healthcare Investors Q1 2025 Commentary",
      "id": 134895434,
      "image": "",
      "related": "MRNA",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=08a995b94c9843618fb019a74515636093294d133726b11dc86cee43c76ca7fd"
    }
  },
  {
    "ts": null,
    "headline": "Trump Can Reset After Tariffs Ruling, Musk Exit. Why That’s Good for Stocks.",
    "summary": "Trump Can Reset After Tariffs Ruling, Musk Exit. Why That’s Good for Stocks.",
    "url": "https://finnhub.io/api/news?id=eae812ba37886064c28210e09605ac78da8caffca60b5ca963c791dbef0e971f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748587500,
      "headline": "Trump Can Reset After Tariffs Ruling, Musk Exit. Why That’s Good for Stocks.",
      "id": 134895457,
      "image": "",
      "related": "MRNA",
      "source": "MarketWatch",
      "summary": "Trump Can Reset After Tariffs Ruling, Musk Exit. Why That’s Good for Stocks.",
      "url": "https://finnhub.io/api/news?id=eae812ba37886064c28210e09605ac78da8caffca60b5ca963c791dbef0e971f"
    }
  },
  {
    "ts": null,
    "headline": "Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks",
    "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen (NASDAQ:BIIB).",
    "url": "https://finnhub.io/api/news?id=5e602a9d616ac83a6a50a36419ece3ad23b7b2a464982b92055c69e8d8bb99b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748576096,
      "headline": "Q1 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks",
      "id": 134899349,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q1, starting with Biogen (NASDAQ:BIIB).",
      "url": "https://finnhub.io/api/news?id=5e602a9d616ac83a6a50a36419ece3ad23b7b2a464982b92055c69e8d8bb99b2"
    }
  }
]